|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102.55 USD | -2.39% |
|
-2.57% | +4.77% |
| Jan. 20 | RBC Raises Price Target on Incyte to $95 From $92, Keeps Sector Perform Rating | MT |
| Jan. 20 | Wells Fargo Downgrades Incyte to Equalweight From Overweight, Adjusts PT to $107 From $116 | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 20.63B | |||||
| 77.51B | |||||
| 56.2B | |||||
| 58.79B | |||||
| 57.8B | |||||
| 25.5B |
- Stock Market
- Equities
- INCY Stock
- Charts Incyte Corporation
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
